




Amarin Corporation plc  
Investor Relations Department  
2 Pembroke House, Upper  
Pembroke  
Street 28-32  
Dublin 2  
Ireland

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: AMRN**

Last Trade:	3.13
Trade Time:	4:00 PM ET Mar 21, 2018
Change:	-0.07  (- 2.188%)
Day Range	3.11 - 3.29
52-Week Range	2.85 - 4.60
Volume	4,173,005

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Mar 21, 2018

[Amarin Announces First Middle East Approval for Vascepa®](#)

Mar 12, 2018

[Vascepa® \(Icosapent Ethyl\) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein \(hsCRP\)](#)

Mar 12, 2018

[Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs](#)

Mar 5, 2018

[Amarin Announces Closing of Underwriter's Purchase of Additional Shares](#)

Mar 1, 2018

[Amarin Announces Start of Final Clinical Site Visits in the REDUCE-IT Cardiovascular Outcomes Study](#)

## Financials [\[ View all \]](#)

[Fourth Quarter Financial Results](#)

Feb 27, 2018

[Annual Report \(10-K\)](#)

Apr 21, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 1, 2017

[Quarterly Report \(10-Q\)](#)

Aug 2, 2017

[Quarterly Report \(10-Q\)](#)

May 3, 2017

[Quarterly Report \(10-Q\)](#)